Glanzmann thrombasthenia is a rare hereditary disorder that belongs to a group of platelet anomalies characterized by insufficient platelet adhesion to the vascular wall and insufficient thrombus formation when blood vessels are damaged. This disorder is caused by a congenital deficiency of glycoproteins IIb/IIIa, which are responsible for binding to fibrinogen and other molecules involved in hemostasis processes. As a result, individuals suffering from this pathology are prone to frequent and unexplained bleeding, which significantly reduces their quality of life and requires constant monitoring and treatment.
History of the disease and interesting historical facts
Glanzmann thrombasthenia was first described in 1973 by Swiss hematologist A. Glanzmann. His research revealed a link between the deficiency of glycoproteins IIb/IIIa and clinical manifestations such as multiple bleeding. Interestingly, the disease was named after Glanzmann, who became a pioneer in the study of this rare pathology. Since then, the study of Glanzmann thrombasthenia has led to significant advances in medical genetics and diagnostics, allowing doctors to better understand the mechanisms of the disease and develop new treatments.
Epidemiology
Glanzmann thrombasthenia occurs with a frequency of approximately 1 in 1,000,000 population, making it one of the rarest platelet dysfunctions. The disease has an autosomal recessive type of inheritance, which explains the low frequency of its occurrence. In most cases, Glanzmann thrombasthenia is diagnosed in childhood or adolescence, and the disease occurs with equal frequency in men and women. There are regional differences in prevalence, with the greatest number of cases registered in countries with high genetic diversity of the population.
Genetic predisposition to this disease
The main cause of Glanzmann's thrombasthenia is mutations in the genes encoding glycoproteins IIb and IIIa, located on chromosome 17 (ITGB3 and ITGA2B genes, respectively). These genes are responsible for the synthesis of integrins, which are necessary for platelet aggregation. It is known that more than 60 different mutations associated with this disease have been described in the scientific literature. Such mutations can lead to complete or partial defects in the functioning of platelets, complicating their participation in hemostasis. Inheritance of diseases occurs from both parents, which makes the probability of transmission of the disease from carriers quite high, especially in small or genetically weakened populations.
Risk factors for the development of this disease
The following factors directly influence the development of Glanzmann's thrombasthenia:
- Heredity: the disease is genetically predetermined.
- Family history: Having similar cases in the family increases the risk of developing the disease.
- Genetic mutations: specific mutations in genes that affect platelet function.
- Comorbidities: Some autoimmune or systemic diseases may indirectly affect platelet counts.
It is important to note that Glanzmann's thrombasthenia is not caused by environmental or lifestyle factors, which distinguishes it from many other diseases of the circulatory system.
Diagnosis of this disease
Diagnosis of Glanzmann thrombasthenia is based on clinical and laboratory data, as well as specialized studies.
- Main symptoms: frequent and unexplained bleeding, hematomas, ecchymosis, prolonged bleeding after injuries and surgeries.
- Laboratory tests: complete blood count, coagulation tests, platelet function tests. Specific tests include platelet adhesion test and platelet aggregation in response to various agents.
- Radiologic tests: Use of ultrasound and other imaging techniques to detect hematomas or platelet abnormalities.
- Other diagnostics include molecular genetics to identify specific mutations and diagnostics under the guidance of hematology specialists.
- Differential diagnosis: it is necessary to exclude other hemostatic disorders such as von Willebrand disease and thrombocytopenia.
This comprehensive approach allows us to accurately determine the presence of Glanzmann thrombasthenia and assess its severity.
Treatment
Treatment of Glanzmann thrombasthenia should be individualized and aimed at controlling symptoms and preventing complications.
- General treatment: use of specific methods of bleeding control, such as local hemostatic agents, platelet transfusions and other forms of therapeutic measures.
- Pharmacological treatment: administration of antifibrinolytic drugs such as tranexamic acid and other hemostatic agents that promote increased platelet adhesion.
- Surgery: In severe cases, removal of the spleen (splenectomy) may be necessary to improve platelet function and reduce bleeding.
- Other treatments: Participating in physical therapy and rehabilitation programs can be very helpful in the recovery process.
Effective treatment largely depends on the level of understanding of the disease mechanisms and the progression of the clinical picture.
List of medications used to treat this disease
- Tranexamic acid
- Desmopressin
- Etamsilate
- Factor VIII (if needed)
- Platelet concentrates (for low platelet counts)
These medications help control symptoms and prevent complications associated with Glanzmann thrombasthenia.
Disease monitoring
Management of Glanzmann thrombasthenia includes regular examinations and monitoring of the patient's condition.
- Control stages: regular checks of platelet function, examination plans every 6-12 months, depending on the severity of the disease.
- Prognosis: With proper treatment and monitoring, many patients can effectively control their symptoms and lead normal lives.
- Complications: Serious complications are possible due to many factors, including patients with severe forms who are at increased risk of blood clots.
Thus, an important aspect for successful disease control is routine monitoring of platelet health and functionality.
Age-related features of the disease
Taking into account age indicators, Glanzmann thrombasthenia can manifest itself with different symptoms in different age groups, from early childhood to old age.
- Children: Symptoms of the disease may appear several months or years after birth, often accompanied by prolonged bleeding after injury.
- Adolescents and young adults: Severe bleeding may occur at this age, including during surgery.
- Adults: In some patients, symptoms may improve with age, although overall the risk of serious complications remains.
This information highlights the need for a differentiated approach to patients in different age groups.
Questions and Answers
- What are the main symptoms of Glanzmann's thrombasthenia? The main symptoms include frequent nosebleeds, gum bleeding, internal bleeding, and hematomas.
- How is Glanzmann's thrombasthenia diagnosed? Diagnosis includes clinical examination, laboratory tests for platelet adhesion and aggregation, and genetic testing.
- Is it possible to completely cure Glanzmann's thrombasthenia? There is no complete cure, but treatment can control symptoms and reduce the risk of complications.
- How should a patient with Glanzmann's thrombasthenia be cared for? It is necessary to avoid injuries, monitor the state of platelets and strictly follow the recommendations of the attending physician.
- What to do if you have symptoms of Glanzmann thrombasthenia? If symptoms appear, you should consult a hematologist for examination and prescription of adequate treatment.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends that patients with Glanzmann's thrombasthenia follow these simple but important rules:
- Maintain regular contact with your doctor and have routine checkups to monitor your platelet status.
- Avoid injuries and situations that may cause bleeding, especially when playing sports.
- Discuss with your doctor the possible use of medications to increase clotting, especially before elective surgery.
- Keep your family and friends informed about your condition so that they can be ready to help if needed.
- Monitor your emotional state, as stress can negatively affect your health.
These tips can help improve quality of life and reduce the risk of complications in patients with Glanzmann thrombasthenia.
